復星醫藥(02196.HK):復星醫藥產業擬出資9000萬元增資杏脈科技
格隆匯1月25日丨復星醫藥(02196.HK)發佈公吿,2022年1月24日、復星醫藥產業、亞東智健、寧波復脈及目標公司(即上海杏脈信息科技有限公司)訂立投資協議,內容有關(其中包括)向目標公司增資。復星醫藥產業擬以現金及其對目標公司享有的債權本金出資合計人民幣9000萬元。
根據投資協議,亞東智健合計出資人民幣2.10億元(其中包括現金人民幣4340萬元及對目標公司享有的人民幣1.666億元債權本金)認繳目標公司新增註冊資本人民幣3500萬元;復星醫藥產業合計出資人民幣9000萬元(其中包括現金人民幣1860萬元及對目標公司享有的人民幣7140萬元債權本金)認繳目標公司新增註冊資本人民幣1500萬元;及寧波復脈現金出資人民幣3750萬元,以認繳目標公司新增註冊資本人民幣625萬元。本次增資款擬主要用於滿足目標公司的研發投入、市場推廣及日常運營等。復星醫藥產業擬以自籌資金支付本次增資對價。
根據披露,杏脈科技系一間專注於研發、生產、銷售醫療影像及病理人工智能軟件及數字化解決方案的科創型企業,部分產品於2021年開始進入商業化,目前仍處於投入期。本次增資旨在解決目標公司現階段研發投入、市場推廣及日常運營的資金需求,將復星醫藥產業、亞東智健截至本次增資前對目標公司享有的存續債權轉換為資本出資,以及進一步加強對目標公司員工的激勵。本次增資前,公司透過復星醫藥產業及佛山禪醫合共持有目標公司30%的權益。本次增資完成後,復星醫藥產業持有目標公司的股權比例將由25%增至約25.88%,公司透過復星醫藥產業及佛山禪醫將合共持有目標公司約28.24%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.